RMD vs WST — Key Metrics

Metric RMD (RESMED INC) WST (WEST PHARMACEUTICAL SERVICES INC)
Price242.61404.02
Market Cap34.12 Billion28.14 Billion
P/E (TTM)22.0445.04
P/B (Quarterly)5.4389.779
P/S (TTM)5.958.29
Net Profit Margin (TTM)27.818.8
Gross Margin (TTM)61.137.6
ROE (TTM)25.121.1
Revenue Growth YoY (TTM)n/an/a

Upfront Investment - S&P 500 Stock Comparison & AI Analysis

AI-powered analysis and comparison tools for S&P 500 stocks, helping investors make data-driven decisions with delayed market data and portfolio modeling.

RESMED INC
vs
 
WEST PHARMACEUTICAL SERVICES INC
 
RESMED INC
vs
 
WEST PHARMACEUTICAL SERVICES INC
Performance Comparison
AI Model Recommendation
RMD · RESMED INC

Outperform

46
UnderperformOutperform
WST · WEST PHARMACEUTICAL SERVICES INC

Greatly Underperform

-95
UnderperformOutperform
Recommendation Summary

Stock RMD is projected to outperform the market, stock WST is projected to greatly underperform the market. Upfront Recommendation: RMD.

Financial Metrics
Prices delayed ~15 min
RMD Metrics WST
$242.61 Price $404.02
— Market Capitalization —
22.04 Price to Earnings Ratio 45.04
5.95 Price to Sales 8.29
21.21 Price to FCF Ratio 48.5
9.75 Price to Gross Profit 22.04
86.65 Price to R&D 372.28
9.73 Price to Current Assets 15.49

RMD vs WST at a glance

Resmed INC (RMD) and West Pharmaceutical Services INC (WST) are both Medical Instruments & Supplies companies in the Healthcare sector. RMD is the larger, at $34.1 billion in market value against $28.1 billion for WST, about 1.2 times the size.

On trailing-twelve-month figures, RMD trades at 22.0 times trailing earnings and WST at 45.0; net profit margins are 27.8% and 18.8%.

The Upfront Investment model currently rates RMD Outperform and WST Greatly Underperform as of November 18, 2026. The rating ranks the model's medium-term return forecast against the other stocks it scores; it is a statistical forecast, not investment advice.